Audit: QRS - sh-Polypeptide-71 for Hair Regrowth
Audit conducted on 11/12/2026 05:02 using AI4L + evidence-mcp / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 97 |
| Passed | 87 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Lede, Protocol, Time to effect, gates, tiers and Monitoring all trace to ER Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications and Monitoring text |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no human data”, “no topical data”, “may cause”, “could lower … if the peptide is absorbed” kept from the ER |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications from “Populations who should avoid”; interactions from the theoretical group; no modifying factor relabeled |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | HR3 Matrix Hair Solution Alpha, Hairgen Booster and KeraFactor appear in the ER for the same facts; no PMIDs, NCT IDs or expert names |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is expert, accessible, objective, and data-driven | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses the reader directly — it presents evidence, not guidance | 🟢 | No second-person address |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms (granulomatous, anticoagulation, PDE5 inhibitors, phototrichogram, SALT score) are ER labels carried verbatim |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.10 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.11 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede frames the verdict for “adults willing to follow demanding routines” |
| 2.13 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording |
| 2.14 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial route-of-administration or consumer-grade terms |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and column headers unchanged |
| 3.2 | Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name | 🟢 | All template data-qrs-var names present; marker_# and qualitative_item_# expanded to 1..n |
| 3.3 | Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well | 🟢 | Markup outside the spans matches the template; only display:none on empty tiers and pipeline metadata fields (duration, git_user, git_issue) differ |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. | 🟢 | Empty High/Medium tiers and Speculative risks hidden; no empty-state text |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and interaction labels use the ER bold labels (example lists trimmed, glosses dropped) |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji |
| 4.5 | The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. | 🟢 | No trailing dash clauses, glosses, untrimmed example lists or repetitions found |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | duration quoted because the value contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.11.9 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-1112-0444 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Opus |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Opus 5.5 |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “sh-Polypeptide-71 for Hair Regrowth - Quick Reference Sheet” |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 11/12/2026 from 2026-1112-0444 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “a lab-made copy of a nerve-released signaling peptide, is a cosmetic ingredient in hair and lash products marketed for thicker hair” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the four Conclusion paragraphs |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven “Populations who should avoid” items present |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales and citations stripped |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “needle-assisted use”, “no human data” and “no topical data” kept |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in contraindication parentheses |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names avoid-populations |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found | 🟢 | ER “Documented interactions:” is “None identified”; caution_items empty |
| 9.3 | [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label | 🟢 | All eight theoretical interactions present |
| 9.4 | The ER placeholder “None identified” is never an item: it means that group is empty | 🟢 | |
| 9.5 | Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause | 🟢 | No “(theoretical)”, “inferred from” or mechanism clauses (“through reduced platelet function”, “since …” stripped) |
| 9.6 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mitigation sentences stripped |
| 9.7 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists kept in trimmed form |
| 9.8 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in interaction parentheses |
| 9.9 | If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | ER theoretical group is not empty |
| 9.10 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated |
| 9.11 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. | N/A | Section not empty (theoretical interactions present) |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Therapeutic Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from that section | 🟢 | Microneedling-assisted regimen, laser-assisted regimen and leave-on products |
| 10.3 | If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER provides three or more actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. | 🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Density (microneedling, laser) and hair shaft thickness timepoints |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Density sets precede the conflicted hair shaft thickness set |
| 11.3 | If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER provides three time-to-effect aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | High and Medium spans hidden |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | High, Medium and Speculative spans hidden |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names |
🟢 | Three biomarker rows: hair density, SALT score, blood pressure and pulse |
| 14.3 | [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” | 🟢 | Targets as in ER table |
| 14.4 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. | 🟢 | |
| 14.5 | If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template |
N/A | ER names measurable biomarkers |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 15.2 | All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … |
🟢 | Four qualitative markers listed |
| 15.3 | If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template |
N/A | ER names qualitative markers |
Issues 11/12/2026 05:02
Pass rate 100.00%. No issues found.
Issues 11/12/2026 04:58
- 14.4 — Cadence drops baseline readings: The monitoring cadence at line 654 lists only the baseline phototrichogram, photographs and hair-loss stage, omitting the ER baseline SALT score for alopecia areata and the baseline resting blood pressure and pulse for low or variable blood pressure, which the SALT and blood-pressure targets (lines 633, 644) rely on.
Fixes 11/12/2026 04:58
- 14.4 — Cadence baseline readings added: Added “plus SALT score in alopecia areata and resting blood pressure and pulse if blood pressure is low or variable” to the baseline part of the monitoring cadence, as in the ER.
Issues 11/12/2026 04:55
- 1.2 / 1.3 — Hedge “if any” dropped: The At-A-Glance at line 439 reads “whose benefit cannot yet be separated from delivery”, dropping the ER Conclusion’s “if any” (“whose benefit, if any, is not yet separable from the methods used to deliver it”) and thereby presupposing a benefit.
Fixes 11/12/2026 04:55
- 1.2 / 1.3 — Hedge “if any” restored: Changed the At-A-Glance ending from “whose benefit cannot yet be separated from delivery” to “whose benefit, if any, cannot yet be separated from delivery”, trimming “and” and “hair” elsewhere in the lede to stay at 70 words.
Issues 11/12/2026 04:50
- 2.12 / 7.2 — Lede omits audience verdict: The at_a_glance lede (line 439) summarizes only Conclusion paragraphs 1-3 and drops the ER’s execution-oriented takeaway for this audience, “For adults willing to follow demanding hair routines, the ingredient remains an unproven add-on”.
- 4.5 — Repeated regimen in time cell: time_1_sub (line 495) “Of twice-weekly needling sessions” repeats action_1_value “Twice weekly for 16–20 weeks” (line 453).
- 4.5 — Example lists left untrimmed: Five theoretical interaction labels (lines 571, 573, 575, 576, 577) carry all three ER examples, e.g. “(amlodipine, lisinopril, oral minoxidil)”, instead of a trimmed list.
Fixes 11/12/2026 04:50
- 2.12 / 7.2 — Lede gains audience verdict: Added the ER Conclusion’s takeaway “For adults willing to follow demanding hair routines, it remains an unproven add-on whose benefit cannot yet be separated from delivery” and tightened earlier wording to stay at 70 words.
- 4.5 — Removed repeated regimen: time_1_sub changed from “Of twice-weekly needling sessions; absence of change by 20 weeks suggests a non-response” to “Absence of change by 20 weeks suggests a non-response”.
- 4.5 — Trimmed example lists: Cut five theoretical interaction labels from three ER examples to two (dropped lisinopril, naproxen, high-dose vitamin E, L-citrulline, laser or light devices).
Issues 11/12/2026 04:46
- 1.3 — Minoxidil hedge dropped: Key Interactions line 570 states “more stinging and greater absorption on freshly needled scalp” where the ER says topical minoxidil “may cause more stinging and greater absorption”.
- 2.7 — Undefined acronym VIP: Key Interactions lines 571 and 576 use “if VIP is absorbed” although the QRS never introduces the acronym, so readers cannot tell it refers to the peptide.
- 2.14 — Lay route phrasing: At a Glance line 439 says the ingredient was “pressed into the scalp with a needle stamp” rather than using the formal term “microneedling”, as the ER does throughout.
Fixes 11/12/2026 04:46
- 1.3 — Minoxidil hedge restored: Changed the Topical minoxidil item from “more stinging and greater absorption” to “may cause more stinging and greater absorption”, matching the ER.
- 2.7 — Undefined acronym VIP: Replaced “if VIP is absorbed” with “if the peptide is absorbed” in the blood pressure–lowering drugs and nitric-oxide-raising supplements items.
- 2.14 — Lay route phrasing: Changed the At a Glance phrase “pressed into the scalp with a needle stamp or delivered by laser” to “delivered into the scalp by microneedling or laser”.